Every 8-K that Blade Air Mobility, Inc. (BLDE) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 8-K covers material events a company has to report between its quarterly reports, so if you follow BLDE and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full BLDE filings page.
Strata Critical Medical, Inc. reported results of its annual stockholder meeting held on May 28, 2026. Stockholders elected Class II directors William A. Heyburn and Andrew Lauck to serve until the 2029 annual meeting. Heyburn received 46,050,902 votes for and 505,421 withheld, while Lauck received 39,525,159 for and 7,031,164 withheld, with 12,687,496 broker non-votes for each.
Stockholders also ratified Deloitte & Touche LLP as independent registered public accounting firm for the year ending December 31, 2026, with 58,946,832 votes for, 65,815 against, and 231,172 abstentions. In an advisory vote, stockholders approved executive compensation with 38,497,962 votes for, 8,022,682 against, 35,679 abstentions, and 12,687,496 broker non-votes.
Strata Critical Medical reported strong first quarter 2026 results, with total revenue rising 87.4% year-over-year to $67.4 million, driven by 32.4% growth in Logistics revenue and the addition of its Clinical business. Gross profit doubled to $14.1 million, lifting gross margin to 21.0% from 19.6%.
The company generated net income from continuing operations of $2.4 million, compared with a loss of $1.6 million a year earlier, and delivered Adjusted EBITDA of $6.4 million, up sharply from $0.4 million. Operating cash flow reached $3.9 million, and Strata ended the quarter with $58.8 million in cash and short-term investments.
Clinical revenue rose 12.7% sequentially to $19.8 million, with Clinical gross profit up 29.2% versus Q4 2025. The company completed a bolt-on acquisition of Ohio Valley Perfusion Associates and reiterated its full-year 2026 guidance for revenue of $260–275 million, Adjusted EBITDA of $29–33 million, and free cash flow before aircraft and engine acquisitions of $15–22 million.
Strata Critical Medical reported very strong growth for Q4 2025, with revenue rising 83.5% year over year to $66.8 million. Logistics revenue, which reflects organic growth, increased 35.3% to $49.2 million, while new Clinical operations contributed $17.6 million following the Keystone acquisition.
Gross profit nearly doubled to $14.4 million and gross margin improved to 21.6%. The net loss from continuing operations narrowed to $5.4 million, but the company remained unprofitable on a GAAP basis. Non-GAAP Adjusted EBITDA jumped to $7.0 million from $1.1 million.
For full year 2025, revenue reached $197.1 million and Adjusted EBITDA was $14.1 million, both above the high end of guidance. Strata raised its 2026 outlook to revenue of $260–275 million and Adjusted EBITDA of $29–33 million, and now expects free cash flow before aircraft and engine acquisitions of $15–22 million.
Strata Critical Medical, Inc. entered into a new secured, asset-based revolving credit facility of up to $30.0 million with JPMorgan Chase Bank, N.A. and other lenders. The agreement allows the facility to be increased by up to an additional $20.0 million, providing extra borrowing capacity if conditions are met.
The ABL facility matures on January 30, 2029 and will bear interest, at Trinity Air Medical’s election, at an adjusted Term SOFR-based fixed rate plus a 2.00% margin or a one‑month Term SOFR floating rate plus a 2.00% margin. A 0.25% annual commitment fee applies to unused amounts.
The loans are guaranteed by Strata Critical Medical and its subsidiary Strata Critical, Inc. and are secured by first‑priority liens on substantially all personal property of the loan parties. The agreement contains customary covenants and events of default, including a springing minimum fixed charge coverage ratio of 1.05 to 1.00 when availability falls below specified thresholds. Proceeds are intended for working capital and general organizational purposes.
Strata Critical Medical, Inc. furnished a Form 8-K to announce it issued a press release with financial results for the third quarter ended September 30, 2025. The press release is attached as Exhibit 99.1 and incorporated by reference.
The disclosure is provided under Item 2.02, Results of Operations and Financial Condition, and is designated as furnished, not filed, under the Exchange Act.
Strata Critical Medical, Inc. completed the acquisition of Keystone Perfusion Services, LLC on September 16, 2025. The buyer paid a base Purchase Price of $124 million (subject to adjustment), with payment structured eighty percent in cash and twenty percent in Strata common stock, plus up to $23 million of contingent consideration tied to performance over the next 12, 24 and 36 months.
The Purchase Price can be adjusted downward or upward by up to $12.4 million based on Keystone's 2025 adjusted EBITDA relative to specified thresholds. At Closing, after adjustments and expenses, Seller received roughly 88% cash and 12% stock. Strata issued 3,434,607 shares in reliance on exemptions from registration and obtained representation and warranty insurance as primary recourse for certain breaches. The filing includes a standard cautionary note on forward-looking statements and lists customary surviving reps, warranties and covenants.
Strata Critical Medical, Inc. filed an 8-K reporting several corporate governance changes, including a name change and the appointment of Co-Chief Executive Officers. The filing states the board will require independent members to elect a Lead Independent Director whenever the chairman is not independent or previously served as an officer, and describes the powers and duties of that role. The company amended bylaws to limit the number of stockholder-nominated director candidates at a meeting to the number of directors up for election and to revise procedural mechanics and disclosure obligations for nominations, proposals, and proxy solicitations. Additional bylaw changes address adjournments and align provisions with the Delaware General Corporation Law, plus clarifying and technical edits. The filing is dated August 29, 2025 and is signed by William A. Heyburn as Co-Chief Executive Officer and Chief Financial Officer.
Strata Critical Medical, Inc. filed an amended report to add details about compensation for its new Co-Chief Executive Officers, Melissa Tomkiel and William Heyburn, following the closing of an equity purchase agreement. Effective as of the closing, the board increased each executive’s base salary to $550,000.
Each co-CEO was also granted performance-based restricted stock units (PSUs) under the 2021 Omnibus Incentive Plan, with a target value of $500,000 tied to Passenger business financial targets over the 12 months after closing and $2,000,000 tied to company financial performance over a three-year period. The board approved enhanced equity treatment if either executive is terminated without Cause or resigns for Good Reason, including accelerated vesting of certain time-based awards and prorated vesting of performance awards based on actual results. These terms are reflected in offer letters entered into on August 28, 2025.